A string of executive actions issued by President Donald Trump during his first weeks in the White House triggered widespread uncertainty across government agencies.
Some orders have been particularly impactful in healthcare.
Last week, the White House issued a freeze on communications from health-related agencies, which rippled through a number of federal initiatives. The National Institutes of Health, for example, canceled a meeting on antibiotic resistance.
Meanwhile, in some ways, the FDA has been going about business as usual. The agency issued several drug approvals last week, for example, including the first nod for a new type of pain medication in decades.
Yet other aspects of the FDA’s work appear up in the air.
A Feb. 5 adcomm meeting to discuss new post-marketing rules for opioids is now missing from the agency’s…